Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
250 participants
OBSERVATIONAL
2025-12-01
2026-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
NCT06956092
Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy
NCT04703686
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
NCT05533775
Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL Study
NCT05927558
A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma
NCT06670105
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients treated in EPA
Patients treated in Expanded Access Program to Glofitamab
Glofitamab
Glofitamab received for DLBCL in Early Phase Access
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Glofitamab
Glofitamab received for DLBCL in Early Phase Access
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patient who received at least Obinutuzumab pretreatment and one infusion of Glofitamab
* adult patient
* patient who is informed of the study and who did not oppose to their data collection
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Lymphoma Academic Research Organisation
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guillaume MANSON, MD
Role: STUDY_CHAIR
Lymphoma Study Association
Gilles CROCHET, MD
Role: STUDY_CHAIR
The Lymphoma Academic Research Organisation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CH Victor Dupouy
Argenteuil, , France
CH d'Avignon - Hôpital Henri Dufaut
Avignon, , France
CH de la Côte Basque
Bayonne, , France
CHRU Besançon - Hôpital Minjoz
Besançon, , France
Hopital D'Instruction Des Armees Percy
Clamart, , France
Hopital Henri Mondor
Créteil, , France
CHU de Dijon - Hôpital le Bocage
Dijon, , France
CH de Dunkerque
Dunkirk, , France
CHU de Grenoble - Hôpital Albert Michallon
La Tronche, , France
Hôpital de Libourne
Libourne, , France
CHRU de LILLE - Claude Huriez
Lille, , France
Hopital Saint Vincent-de-Paul
Lille, , France
Centre Léon Bérard
Lyon, , France
INSTITUT PAOLI CALMETTES - Service Hématologie
Marseille, , France
Clinique du Pont de Chaume
Montauban, , France
CH de Mulhouse Sud Alsace
Mulhouse, , France
CHR d'Orléans
Orléans, , France
Hopital Saint-Louis
Paris, , France
Chu de Bordeaux - Hopital Haut-Leveque
Pessac, , France
CHU Lyon Sud
Pierre-Bénite, , France
CHU de Poitiers - Hôpital de La Milétrie
Poitiers, , France
CH de Quimper Cornouaille
Quimper, , France
CHU de Rennes - Hôpital de Pontchaillou
Rennes, , France
Institut Curie - Site Saint-Cloud
Saint-Cloud, , France
CHU de Strasbourg
Strasbourg, , France
Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse, , France
Chu Bretonneau
Tours, , France
CHRU de Nancy - Hôpital de Brabois
Vandœuvre-lès-Nancy, , France
Ch de Bretagne Atlantique
Vannes, , France
Gustave Roussy Cancer Campus Grand Paris
Villejuif, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Driss CHAOUI, MD
Role: primary
Hacene ZERAZHI, MD
Role: primary
Sophie BERNARD, MD
Role: primary
Adrien CHAUCHET, MD
Role: primary
Xavier PHINA-ZIEBIN
Role: primary
François LEMONNIER, MD
Role: primary
Cédric ROSSI, MD
Role: primary
Christophe FRUCHART, MD
Role: primary
Sylvain CARRAS, MD
Role: primary
Gaelle LABOURE, MD
Role: primary
Franck MORSHHAUSER, MD
Role: primary
Sandy AMORIM, MD
Role: primary
Laure LEBRAS, MD
Role: primary
Gabriel BRISOU, MD
Role: primary
Reda TABRIZI, MD
Role: primary
Bernard DRENOU, MD
Role: primary
Marlène OCHMANN, MD
Role: primary
Catherine THIEBLEMONT, MD
Role: primary
François-Xavier GROS, MD
Role: primary
Hervé GHESQUIERES, MD
Role: primary
Stéphanie GUIDEZ, MD
Role: primary
Ronan LE CALLOCH, MD
Role: primary
Roch HOUOT, MD
Role: primary
Clémentine SARKOZY, MD
Role: primary
Luc-Mathieu FORNECKER, MD
Role: primary
Loïc YSEBAERT, MD
Role: primary
Laurianne DRIEU LA ROCHELLE, MD
Role: primary
Pierre FEUGIER, MD
Role: primary
Antoine BONNET, MD
Role: primary
Vincent RIBRAG, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GloRel
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.